NEW YORK (GenomeWeb News) – Investment bank Thomas Weisel Partners has increased its fourth-quarter and full-year 2009 revenue guidance for Affymetrix, two weeks before the firm is scheduled to report its results.

Analyst Peter Lawson said that the bank has increased its Q4 estimate to $83 million from its previous estimate of $82 million, slightly above analysts' consensus estimate of $82.8 million. It also lowered the firm's loss per share to $.10 from $.11, in line with the consensus estimate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.